Related Experiment Video
Updated: Aug 16, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
The Effect of Commonly Used Fixed-Dose Single Pill Combinations of Renin-Angiotensin-System Blockers and Calcium
Angelos Liontos1, Dimitrios Biros1, Christos Papagiannopoulos2
1First Department of Internal Medicine, Faculty of Medicine, University Hospital of Ioannina, University of Ioannina, Ioannina, Greece.
Insights
Telmisartan plus amlodipine combination therapy significantly improved insulin resistance in hypertensive patients with impaired fasting glucose. Other drug combinations showed neutral or unfavorable effects on insulin sensitivity.
Area of Science:
- Cardiovascular Pharmacology
- Metabolic Syndrome Research
- Hypertension Management
Background:
- Investigating the impact of antihypertensive drugs on glucose metabolism and insulin resistance.
- Renin-angiotensin system (RAS) blockers may benefit glucose metabolism, while calcium channel blockers (CCBs) have neutral effects.
- Differential effects on glycemic indices exist within antihypertensive drug classes.
Discussion:
- Comparing fixed-dose single pill combinations of RAS blockers and CCBs for their effects on insulin resistance.
- Evaluating homeostatic model assessment for insulin resistance (HOMA-IR) changes in hypertensive patients with impaired fasting glucose.
- Assessing the impact of valsartan/amlodipine, delapril/manidipine, and telmisartan/amlodipine on insulin resistance.
Key Insights:
- Telmisartan/amlodipine combination therapy significantly reduced HOMA-IR by 22.55% (p <0.01).
- Valsartan/amlodipine showed a slight increase in HOMA-IR (1.4%, p = 0.57), while delapril/manidipine showed a 12.65% increase (p = 0.072).
- Significant differences in HOMA-IR changes were observed between telmisartan/amlodipine and the other two combinations.
Outlook:
- Telmisartan/amlodipine combination demonstrates a favorable effect on insulin resistance compared to valsartan/amlodipine and delapril/manidipine.
- Further research into the specific mechanisms underlying these differential metabolic effects is warranted.
- Clinical implications for managing hypertension and metabolic disturbances in co-morbid patients.
Abstract:
Backround: The effect of antihypertensive drugs on glucose homeostasis and insulin resistance remains an issue under investigation. There is evidence that renin-angiotensin system (RAS) blockers may favorably affect glucose metabolism, while treatment with calcium channel blockers (CCBs) is considered to have an overall neutral metabolic effect. However, the effects on glycemic indices may differ among agents within the same class of antihypertensive drugs. Objective: To evaluate the effects of different fixed-dose single pill combinations of RAS blockers with CCBs on homeostatic model assessment for insulin resistance (HOMA-IR). Methods:Drug-naive patients with arterial hypertension (AH) and impaired fasting glucose (IFG) were randomly allocated to open-label fixed, single pill combinations of valsartan 160 mg/day plus amlodipine 5 mg/day (VAL/AMLO group, n = 54), delapril 30 mg/day and manidipine 10 mg/day (DEL/MANI group, n = 53) or telmisartan 80 mg/day and amlodipine 5 mg/day (TEL/AMLO group, n = 51) for 12 weeks. Glycemic indices and HOMA-IR were determined at baseline and post-treatment. Results:A total of 158 patients were included. All treatment combinations effectively reduced blood pressure (systolic and diastolic) to similar levels (all p < 0.001). A decrease in the HOMA-IR index by 22.55% (p <0.01) was noted following treatment with TEL/AMLO, while an increase by 1.4% (p = 0.57) and 12.65% (p = 0.072) was observed in the VAL/AMLO group and the DEL/MANI group, respectively. These changes were significantly different between TEL/AMLO and DEL/MANI (p < 0.05) as well as between TEL/AMLO and VAL/AMLO (p < 0.001). Conclusion:Despite similar antihypertensive action, the effect of fixed, single pill combinations with TEL/AMLO, VAL/AMLO and DEL/MANI on insulin resistance is in favor of TEL/AMLO. Trial registration: The study protocol was published online in https://diavgeia.gov.gr/ (No: ÂÈ6Ó46906Ç-ÁÅÓ) via the Ministry of Digital Governance, after receiving approval from the Scientific Council and Administrative Council of University Hospital of Ioannina (No. of approval: 1/12-06-2014 (issue 150). https://diavgeia.gov.gr/decision/view/%CE%92%CE%986%CE%A346906%CE%97- %CE%91%CE%95%CE%A3 h t t p s : / / d i a v g e i a . g o v . g r / d o c / % C E % 9 2 % C E % 9 8 6 % C E % A 3 4 6 9 0 6 % C E % 9 7 - %CE%91%CE%95%CE%A3?inline=true.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Hypertension IV: Drug Therapy and Lifestyle Modifications

